Co-managing skin and joint disease: Use of TNFi

Speciality: All Speciality

Description:

A warm welcome to all the medical professionals in this interesting session on Co-managing skin and joint disease: Use of TNFi
Co-managing skin and joint diseases, particularly in conditions like psoriatic arthritis (PsA), requires an integrated approach. Tumor necrosis factor inhibitors (TNFi) have proven highly effective in addressing both joint inflammation and skin lesions. Psoriatic arthritis, which causes joint pain and swelling, often coexists with psoriasis, a skin condition characterized by red, scaly patches. TNFi therapy targets the underlying inflammatory pathways, helping reduce both joint damage and skin symptoms.
The dual benefit of TNFi makes it an essential treatment for patients with combined skin and joint involvement. Drugs like adalimumab and etanercept have shown significant success in reducing joint pain, improving function, and clearing skin lesions. While effective, TNFi therapy requires monitoring for potential side effects, including an increased risk of infections. Despite these risks, TNFi have transformed the management of psoriatic arthritis and similar conditions, offering a comprehensive solution for patients dealing with both skin and joint disease.
Therefore, get an overall knowledge of Co-managing skin and joint disease: Use of TNFi
 

See More Webinars @ Hidoc Webinars